Clinical

Dataset Information

0

Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.


ABSTRACT: Interventions: 1 cycle is 28days. Nintedanib (150mg or 200mg) is orally administered twice daily and TAS-102 (35mg/m2) is orally administered twice daily in 1-5days and 8-12 days Primary outcome(s): 16 weeks progression free survival rate ( 16W PFS rate) Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2632430 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2628236 | ecrin-mdr-crc
| 2641267 | ecrin-mdr-crc
| 2646936 | ecrin-mdr-crc
| 2634299 | ecrin-mdr-crc
| 2615622 | ecrin-mdr-crc
2020-12-21 | GSE158713 | GEO
2022-09-06 | GSE210020 | GEO
2023-04-13 | GSE182833 | GEO
2023-04-13 | GSE218575 | GEO
| PRJNA904345 | ENA